Sym015 shows superior specificity compared to TKIs for NSCLC

Bookmark and Share
Published: 29 May 2020
Views: 353
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

Dr Ross Camdige speaks to ecancer online about his ASCO 2020 virtual presentation which discussed Sym015 for NSCLC.

Sym015, a mixture of 2 humanised antibodies, triggers MET degradation by a unique mechanism with superior specificity compared to tyrosine kinase inhibitors (TKIs).

Combination with MET TKI to delay or prevent resistance should be further explored.